Shopping Cart
Remove All
Your shopping cart is currently empty
PF-1355 (PF 06281355) is a selective 2-thiouracil mechanism-based MPO inhibitor. PF-1355 is used for treatment of vasculitic diseases.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $30 | In Stock | In Stock | |
| 5 mg | $43 | In Stock | In Stock | |
| 10 mg | $73 | In Stock | In Stock | |
| 25 mg | $118 | In Stock | In Stock | |
| 50 mg | $223 | In Stock | In Stock | |
| 100 mg | $322 | In Stock | In Stock | |
| 200 mg | $460 | In Stock | In Stock | |
| 500 mg | Preferential | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $47 | In Stock | In Stock |
| Description | PF-1355 (PF 06281355) is a selective 2-thiouracil mechanism-based MPO inhibitor. PF-1355 is used for treatment of vasculitic diseases. |
| In vitro | PF-1355 inhibits MPO activity in phorbol ester-stimulated human neutrophils as measured by taurine chlorination (EC50=1.47 μM) as well as lipopolysaccharide-treated human blood measuring residual MPO activity (EC50=2.03 μM) [1]. |
| In vivo | Administering PF-1355 orally diminishes MPO activity in plasma, lessens vascular edema and neutrophil recruitment, and increases circulating cytokines levels. PF-1355 treatment entirely inhibits albuminuria and chronic renal dysfunction in a model of anti-glomerular basement membrane disease [1]. |
| Synonyms | ZINC205721785, PF-06281355, PF 06281355 |
| Molecular Weight | 321.35 |
| Formula | C14H15N3O4S |
| Cas No. | 1435467-38-1 |
| Smiles | COc1ccc(OC)c(c1)-c1cc(=O)[nH]c(=S)n1CC(N)=O |
| Relative Density. | 1.43 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 55 mg/mL (171.15 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.22 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.